摘要
目的 探讨达格列净联合奥拉西坦治疗T2DM合并急性脑梗死(ACI)患者的效益与风险。方法 选取2020年1月至2022年6月于秦皇岛市第一医院综合内科住院治疗的T2DM合并ACI患者122例,分为达格列净治疗组(Dag,n=61)和达格列净联合奥拉西坦治疗组(Dag+Oxi,n=61),比较两组治疗前后生化指标、临床疗效及不良反应。结果 与Dag组比较,Dag+Oxi组治疗后VEGF、NO升高(P<0.05),IL-6、超敏C反应蛋白、TNF-α、同型半胱氨酸、内皮素1降低(P<0.05)。Dag+Oki组总有效率高于Dag组(P<0.05),不良反应发生率低于Dag组(P<0.05)。多准则决策模型分析显示,Dag+Oki组效益-风险总值高于Dag组。结论 达格列净联合奥拉西坦治疗T2DM合并ACI较单药治疗效益更好,不良反应发生率降低。
Objective To explore the benefit and risk of Dapagliflozin combined with Oxiracetam in the treatment of type 2 diabetes mellitus(T2DM)with acute cerebral infarction(ACI).Methods s122 patients with T2DM combined with ACI who were hospitalized in the Department of Comprehensive Internal Medicine of The First Hospital of Qinhuangdao from January 2020 to June 2022 were selected and divided into Dapagliflozin treatment group(Dag,n=61)and Dapagliflozin+Oxiracetam treatment group(Dag+Oxi,n=61).The serum indicators,clinical efficacy and adverse reactions before and after treatment were compared between the two groups.I Results Compared with Dag group,the levels of IL-6,hs-CRP,TNF-α,Hcy and ET-1 decreased after treatment than those in Dag+Oxi group,while VEGF and NO levels increased(P<0.05).Compared with Dag group,the total effective rate in Dag+Oxi group was higher(P<0.05),and the adverse reaction rate was lower(P<0.05).The analysis of the multi criteria decision-making model showed that Dag+Oki group had a higher total benefit risk value than Dag group.Conclusion Dapagliflozin combined with Oxiracetam is more effective in the treatment of T2DM complicated with ACI and significantly reduces the risk of adverse reactions.
作者
佟亚男
孙鲁生
陈锦荣
傅艳芬
张淑丽
谭立明
谢素春
TONG Yanan;SUN Lusheng;CHEN Jinrong(Department of General Medicine,The First Hospital of Qinhuangdao,Qinhuangdao 066000,China)
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2023年第5期340-345,共6页
Chinese Journal of Diabetes
基金
河北省2020年度医学科学研究课题(冀卫办科教(2020)1号)
秦皇岛市科学技术研究与发展计划(201902A103)。
关键词
多准则决策
糖尿病
2型
急性脑梗死
效益
风险
Multi-criteria decision-making analysis
Diabetes mellitus,type 2
Acute cerebral infarction
Benefit
Risk
